0.3692
Precedente Chiudi:
$0.3638
Aprire:
$0.3701
Volume 24 ore:
1.19M
Relative Volume:
0.55
Capitalizzazione di mercato:
$50.02M
Reddito:
-
Utile/perdita netta:
$-119.76M
Rapporto P/E:
-0.2735
EPS:
-1.35
Flusso di cassa netto:
$-55.17M
1 W Prestazione:
+4.50%
1M Prestazione:
-9.27%
6M Prestazione:
-71.16%
1 anno Prestazione:
-91.80%
Applied Therapeutics Inc Stock (APLT) Company Profile
Nome
Applied Therapeutics Inc
Settore
Industria
Telefono
212-220-9226
Indirizzo
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Confronta APLT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
APLT
Applied Therapeutics Inc
|
0.3692 | 50.02M | 0 | -119.76M | -55.17M | -1.35 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
2024-12-02 | Downgrade | UBS | Buy → Neutral |
2024-11-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2024-07-31 | Iniziato | William Blair | Outperform |
2024-03-26 | Iniziato | RBC Capital Mkts | Outperform |
2024-02-22 | Iniziato | Leerink Partners | Outperform |
2022-01-04 | Downgrade | Barclays | Overweight → Equal Weight |
2021-08-27 | Downgrade | Goldman | Neutral → Sell |
2021-06-25 | Ripresa | Goldman | Neutral |
2020-10-08 | Iniziato | Truist | Buy |
2020-04-22 | Iniziato | Goldman | Buy |
2020-02-27 | Iniziato | Barclays | Overweight |
2019-06-10 | Iniziato | Citigroup | Buy |
2019-06-10 | Iniziato | Cowen | Outperform |
2019-06-10 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Applied Therapeutics Inc Borsa (APLT) Ultime notizie
Shareholder Rights Advocates at Levi & Korsinsky Investigate Applied Therapeutics, Inc. (APLT) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Applied Therapeutics, Inc. (NASDAQ:APLT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Applied Therapeutics, Inc. (NASDAQ:APLT) Short Interest Update - MarketBeat
Millennium Management LLC Grows Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Millennium Management LLC Boosts Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Class Action Filed Against Applied Therapeutics, Inc. (APLT)February 18, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. LawsuitAPLT - ACCESS Newswire
BNP Paribas Financial Markets Grows Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Janus Henderson Group PLC Sells 10,505,737 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Columbia Trustee Got Sued for Securities Fraud — Then Left Her Pharma Firm Under a Cloud - The Intercept
Janus Henderson Group PLC Decreases Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Price T Rowe Associates Inc. MD Sells 986,108 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
William Blair Brokers Increase Earnings Estimates for APLT - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Stock Rating Upgraded by Wall Street Zen - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Applied Therapeutics Inc (APLT): An Important Analyst Insights - Stocksregister
Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
Vestal Point Capital LP Acquires 10,355,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug - MSN
Applied Therapeutics’ Rare Disease Treatment Flunks in Late-Stage Trial - NewsBreak: Local News & Alerts
New top-line data from Phase II/III trial of govorestat in CMT-SORD - The Pharma Letter
Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug By Stocktwits - Investing.com India
Applied Therapeutics Presents Full 12-Month Clinical Results and - GuruFocus
APLT Shares Results from INSPIRE Trial on Govorestat at Peripher - GuruFocus
APLT Shares Results from INSPIRE Trial on Govorestat at Peripheral Nerve Society Meeting | APLT Stock News - GuruFocus
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting - The Manila Times
Applied Therapeutics Presents Full 12-Month Clinical - GlobeNewswire
Breakthrough in CMT Treatment: New Clinical Data Shows First-Ever Disease Progression Slowing in 24-Month Study - Stock Titan
Here's Why Amazon Is a Brilliant Buy Now (Hint: It's Not E-Commerce) - The Globe and Mail
Massive News for Apple Stock Investors! - The Globe and Mail
Brokerages Set Applied Therapeutics, Inc. (NASDAQ:APLT) PT at $6.10 - Defense World
Applied Therapeutics’ (APLT) “Sector Perform” Rating Reiterated at Royal Bank of Canada - Defense World
APLT: RBC Capital Reiterates Sector Perform Rating, Price Target Maintained | APLT Stock News - GuruFocus
APLT Reports Financial Position and Advances in Govorestat Resea - GuruFocus
Applied Therapeutics Reports First Quarter 2025 Financial Results | APLT Stock News - GuruFocus
Applied Therapeutics, Inc. SEC 10-Q Report - TradingView
Barclays PLC Sells 27,997 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times
APLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Alyeska Investment Group L.P. Boosts Stock Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Shareholders that Lost Money on Applied Therapeutics, Inc. (APLT) Should Contact Levi & Korsinsky about Pending Class ActionAPLT - ACCESS Newswire
Investors in Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your RightsAPLT - ACCESS Newswire
Applied Therapeutics Inc Azioni (APLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Applied Therapeutics Inc Azioni (APLT) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Funtleyder Leslie D. | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
14,502 |
6,381 |
390,459 |
Chinoporos Constantine | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
447 |
197 |
271,436 |
Funtleyder Leslie D. | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
22,950 |
14,000 |
404,961 |
Perfetti Riccardo | Chief Medical Officer |
Feb 06 '25 |
Sale |
0.61 |
86,078 |
52,508 |
900,775 |
Chinoporos Constantine | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
28,117 |
17,151 |
271,883 |
Funtleyder Leslie D. | Chief Financial Officer |
Aug 22 '24 |
Sale |
5.83 |
13,530 |
78,880 |
277,911 |
Perfetti Riccardo | Chief Medical Officer |
Aug 22 '24 |
Sale |
5.83 |
22,681 |
132,230 |
986,853 |
Shendelman Shoshana | President and CEO |
Aug 13 '24 |
Sale |
6.18 |
357,423 |
2,208,874 |
4,810,430 |
Shendelman Shoshana | President and CEO |
Aug 12 '24 |
Sale |
5.98 |
300,000 |
1,794,000 |
5,167,853 |
Shendelman Shoshana | President and CEO |
Aug 14 '24 |
Sale |
5.93 |
119,591 |
709,175 |
4,690,839 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):